Novo Nordisk's new insulin degludec positive in two Phase II trials
This article was originally published in Scrip
Executive Summary
Novo Nordisk's next-generation basal insulin Degludec (insulin degludec) and Degludec Plus (70% Degludec, 30% Novo Nordisk's NovoLog (insulin aspart)) have met primary endpoints for the treatment of type 2 diabetes in two Phase II trials. On the basis of the trial results, presented for first time at last week's American Diabetes Association (ADA) meeting in Florida, Novo Nordisk has pushed the two therapies into Phase III development.